Correction: A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies: Table 3.
2010 ◽
Vol 16
(6)
◽
pp. 1915-1923
◽
2007 ◽
Vol 22
(1)
◽
pp. 1-10
◽
2007 ◽
Vol 13
(18)
◽
pp. 5549s-5555s
◽
2009 ◽
Vol 98
(9)
◽
pp. 3117-3130
◽
2008 ◽
Vol 6
(12)
◽
pp. 174-175
2008 ◽
Vol 6
(12)
◽
pp. 162
◽